Dare Bioscience, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3655 NOBEL DRIVE, SAN DIEGO, CA, 92122
Mailing Address
3655 NOBEL DRIVE, SAN DIEGO, CA, 92122
Phone
858-926-7655
Fiscal Year End
1231
EIN
204139823
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Adopted a 'dual-path' business model using 503B outsourcing to generate immediate revenue.
- Launched DARE to PLAY™ topical cream to bypass traditional FDA timelines.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.